ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2022 Earnings Call Transcript

Page 5 of 5

Ted Karkus: So, BE-Smart technology is literally taking a sliver of a biopsy €“ of the tissue biopsy. We are actually working on other technologies. And what’s interesting about it, what it’s actually doing, we are studying, and this is proprietary unique proteins. What happens is everybody has a mix of proteins. People with €“ that develop esophageal cancer, the ratio of certain proteins changes. And so the key is to find the right protein markers. And from what I understand, nobody else has uncovered the protein markers that we are currently working with. Those same protein markers could potentially be used for more than just esophageal cancer. Well, first of all, it could be used for more than just testing to predict the esophageal cancer, ultimately, understanding more about those protein markers could help us develop a therapeutic to treat esophageal cancer.

That’s sort of way out there, that’s sort of Phase 2. And then also, at the same time, in parallel, I haven’t even, this is not something I have even gotten into detail on yet. It’s possible we can develop the test to work in a different way where we don’t even need an endoscopy, where it’s a procedure that can be done in a doctor’s office. And I don’t want to go into more detail than that now. So, those are the first. So, there is two to three different ways that this esophageal cancer test could play out, will have enormous potential. It doesn’t exactly answer your question, but I can tell you that’s what we are focused on at the current time.

Fred McDonald: Great. Thank you, Ted.

Ted Karkus: Thank you. Welcome. I think that concludes our call. MJ, is there anyone else?

Operator: No more questions in the queue at this time. I will turn it back to you for closing remarks.

Ted Karkus: Fantastic. So look, we ended up. This was an hour call, which is perfect. That’s what I would have targeted. I hope I didn’t talk too much. I hope everyone got an idea of what we are working on. Everything we are working on is real. There are no guarantees in life. But if you can invest in small cap development stage companies, at least you are investing in a management team that has historically executed, I am also the largest shareholder of the company, so you can bet I am going to continue to execute on behalf of the shareholders. We have a fantastic management team in place. We have a demonstrated history not only over the last 10 years, but over the last 2 years of executing. And now we have horses in the race that we never had before.

And we have assets that we never had before that of enormous potential. We executed the other times we had assets. Cold-EEZE when we took it over. I don’t even know if that had any potential, we turned around and sold for $50 million. What we are working on now 10x, 20x the potential of what we did with Cold-EEZE. And then with our lab, again, we got into the business, we executed literally from the first week we were in the business is ridiculous how much business we did. And now we have all these different assets. And you can bet with us that against us, but we are developing all these different assets, and I would be surprised if at least one of these assets doesn’t turn into something really big. And the truth of the matter is I don’t see why all of the assets aren’t going to turn into something really big.

And with that, I really appreciate everybody joining the call today. And I really appreciate your time and your support or your potential support. And I look forward to updating all of our shareholders probably in the not-too-distant future with a lot of good stuff to come. With that, everybody, have a great day. Thank you so much. And thank you, MJ for hosting the call today.

Operator: Thank you, Ted. The call has now concluded. Thank you for attending today’s presentation. You may now disconnect.

Follow Prophase Labs Inc. (NASDAQ:PRPH)

Page 5 of 5